Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 1/20 | 0.48 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 9/20 | 0.42 |
| ▸ | TYMS | P04818 | 1/20 | 0.39 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.39 |
| ▸ | ANPEP | P15144 | 1/20 | 0.38 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.38 |
| ▸ | LAP3 | P28838 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21523050 | 0.83 | GABBR2 (0.42) | GABBR2GABBR1KDM4EMMP2THRB | |
| SCHEMBL22973720 | 0.81 | GABBR2 (0.40) | GABBR2GABBR1KDM4EMMP2THRB | |
| SCHEMBL7961190 | 0.81 | LAP3 (0.48) | GABBR2GABBR1MMP2FOLH1LAP3 | |
| SCHEMBL19211977 | 0.78 | ENPEP (0.44) | GABBR2GABBR1FOLH1TYMSNAALAD2 | |
| SCHEMBL19212140 | 0.78 | ENPEP (0.44) | GABBR2GABBR1FOLH1TYMSNAALAD2 | |
| SCHEMBL27495619 | 0.76 | FOLH1 (0.60) | GABBR2GABBR1FOLH1NAALAD2 | |
| SCHEMBL19212063 | 0.74 | TYMS (0.52) | GABBR2GABBR1FOLH1TYMS | |
| SCHEMBL14727506 | 0.74 | GABBR2 (0.36) | GABBR2GABBR1KDM4EMMP2THRB | |
| SCHEMBL19212086 | 0.74 | ANPEP (0.39) | GABBR2GABBR1FOLH1ANPEPLAP3 | |
| SCHEMBL781579 | 0.74 | GABBR2 (0.41) | GABBR2GABBR1KDM4EMMP2THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3413934-B1 | IMPROVED TREATMENT OF IMPLANTS WITH PHOSPHONIC ACID COMPOUNDS | NANO BRIDGING MOLECULES SA (CH) | 2021-10-13 | — | — | EP | claimed |
| CN-109195641-B | Improved implant treatment with phosphonic acid compounds | 纳米桥接分子股份公司 | 2021-07-27 | — | — | CN | claimed |
| US-11000627-B2 | Treatment of implants with phosphonic acid compounds | NANO BRIDGING MOLECULES SA (CH) | 2021-05-11 | — | — | US | claimed |
| US-20190038802-A1 | IMPROVED TREATMENT OF IMPLANTS WITH PHOSPHONIC ACID COMPOUNDS | NANO BRIDGING MOLECULES SA (CH) | 2019-02-07 | — | — | US | claimed |
| EP-3413934-A1 | IMPROVED TREATMENT OF IMPLANTS WITH PHOSPHONIC ACID COMPOUNDS | Nano Bridging Molecules SA (CH) | 2018-12-19 | — | — | EP | claimed |
| WO-2017137623-A1 | IMPROVED TREATMENT OF IMPLANTS WITH PHOSPHONIC ACID COMPOUNDS | NANO BRIDGING MOLECULES SA (CH) | 2017-08-17 | — | — | WO | claimed |
| US-8173630-B2 | Multipodal tethers for high-density attachment of redox-active moieties to substrates | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-05-08 | — | — | US | claimed |
| EP-4319823-A1 | PORPHYRIN-HYDROPORPHYRIN COMPOUNDS, COMPOSITIONS COMPRISING THE SAME AND METHODS OF USE THEREOF | North Carolina State University (US) | 2024-02-14 | — | — | EP | disclosed |
| WO-2022216927-A9 | PORPHYRIN-HYDROPORPHYRIN COMPOUNDS, COMPOSITIONS COMPRISING THE SAME AND METHODS OF USE THEREOF | NORTH CAROLINA STATE UNIVERSITY (US) | 2023-09-14 | — | — | WO | disclosed |
| EP-3413934-B1 | IMPROVED TREATMENT OF IMPLANTS WITH PHOSPHONIC ACID COMPOUNDS | NANO BRIDGING MOLECULES SA (CH) | 2021-10-13 | — | — | EP | disclosed |
| CN-109195641-B | Improved implant treatment with phosphonic acid compounds | 纳米桥接分子股份公司 | 2021-07-27 | — | — | CN | disclosed |
| US-11000627-B2 | Treatment of implants with phosphonic acid compounds | NANO BRIDGING MOLECULES SA (CH) | 2021-05-11 | — | — | US | disclosed |
| US-10919904-B2 | Northern-southern route to synthesis of bacteriochlorins | NORTH CAROLINA STATE UNIVERSITY (US) | 2021-02-16 | — | — | US | disclosed |
| US-20070108438-A1 | Multypodal tethers for high-density attachment of redox-active moieties to substrates | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2007-05-17 | — | — | US | disclosed |
| WO-2007053192-A2 | MULTIPODAL TETHERS FOR HIGH-DENSITY ATTACHMENT OF REDOX-ACTIVE MOIETIES TO SUBSTRATES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007047925-A2 | SWALLOWTAIL MOTIFS FOR IMPARTING WATER SOLUBILITY TO PORPHYRINIC COMPOUNDS | NORTH CAROLINA STATE UNIVERSITY (US) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007018807-A2 | METHODS AND INTERMEDIATES FOR THE SYNTHESIS OF PORPHYRINS | NORTH CAROLINA STATE UNIVERSITY (US) | 2007-02-15 | — | — | WO | disclosed |
| US-20070027311-A1 | Methods and intermediates for the synthesis of porphyrins | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-02-01 | — | — | US | disclosed |
| US-20070027312-A1 | Methods and intermediates for the synthesis of porphyrins | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-02-01 | — | — | US | disclosed |
| US-20060194960-A1 | infections, burns, sepsis, ulcers, periodontal disease, atherosclerosis, cosmetic and dermatologic conditions, acne, tissue sealing, neoplastic disease or cancer; active agents in photodynamic therapy, luminescent compounds in flow cytometry, solar cells, light harvesting arrays, molecular memory devices | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194960-A1 | infections, burns, sepsis, ulcers, periodontal disease, atherosclerosis, cosmetic and dermatologic conditions, acne, tissue sealing, neoplastic disease or cancer; active agents in photodynamic therapy, luminescent compounds in flow cytometry, solar cells, light harvesting arrays, molecular memory devices | PCNA, SCD, BCL6 | GABBR2 3223/4885GABBR1 3432/4885KDM4E 4311/4885 |
| US-10919904-B2 | Northern-southern route to synthesis of bacteriochlorins | DLD, HCCS, PPIF | GABBR2 2092/4885GABBR1 2021/4885KDM4E 4549/4885 |
| US-20070027312-A1 | Methods and intermediates for the synthesis of porphyrins | PPOX, DHPS, POR | GABBR2 2302/4885GABBR1 2668/4885KDM4E 3569/4885 |
| US-20070027311-A1 | Methods and intermediates for the synthesis of porphyrins | PPOX, HMBS, CYC1 | GABBR2 2691/4885GABBR1 2854/4885KDM4E 3462/4885 |
| US-20070108438-A1 | Multypodal tethers for high-density attachment of redox-active moieties to substrates | DNMT1, TET1, SOD1 | GABBR2 2305/4885GABBR1 1886/4885KDM4E 901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.